Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Usana Health Sciences (USNA) EBIAT (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBIAT for 17 consecutive years, with -$1.1 million as the latest value for Q1 2026.

  • Quarterly EBIAT fell 123.6% to -$1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.2 million through Jan 2026, down 71.1% year-over-year, with the annual reading at $11.5 million for FY2026, 72.71% down from the prior year.
  • EBIAT for Q1 2026 was -$1.1 million at Usana Health Sciences, up from -$6.5 million in the prior quarter.
  • The five-year high for EBIAT was $31.5 million in Q1 2022, with the low at -$6.5 million in Q3 2025.
  • Average EBIAT over 5 years is $12.9 million, with a median of $12.8 million recorded in 2022.
  • The sharpest move saw EBIAT surged 31.04% in 2023, then plummeted 161.49% in 2025.
  • Over 5 years, EBIAT stood at $12.8 million in 2022, then skyrocketed by 31.04% to $16.8 million in 2023, then tumbled by 73.26% to $4.5 million in 2024, then crashed by 245.45% to -$6.5 million in 2025, then surged by 83.78% to -$1.1 million in 2026.
  • According to Business Quant data, EBIAT over the past three periods came in at -$1.1 million, -$6.5 million, and $10.4 million for Q1 2026, Q3 2025, and Q2 2025 respectively.